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PORTUGAL
Location: Southwestern Europe
Borders: Spain and Atlantic Ocean
Includes Azores and Madeira Islands (Atlantic ocean)
Total area: 92,090 sq km
Population: 10,487,289 persons (December 2012)
Negative population growth rate: negative natural and migration 
growth rates.
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•Congenital hypothyroidism (HC)
•ms/ms (24 IEM, PKU included)
•Cystic Fibrosis (CF, pilot study)
Portuguese National Program for Newborn Screening
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Portuguese National Program for Newborn Screening
•1 national laboratory (400 daily samples)
•Not mandatory program with 99.8% coverage
•Sample collection at hospital or health family centers (3rd-6th day)
•Average age for treatment beginning: 10.1 days
•Results communication: 
•Normal cases – www.diagnosticoprecoce.org
•2nd sample request (mail)
•Immediate sending to specialized medical center (8 centers 
distributed along the country, including islands) 
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Portuguese National Program for Newborn Screening
Total birth prevalence for all screened disorders: 1: 1.659
Newborns Disorders Birth prevalence
3.375.266 PKU / HPA 1: 10.459  
3.343.098 HC 1: 2.986 
820.433 IEM 1: 2.399 
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Method
Analysis of amino acids and acylcarnitines as butyl esters (Rashed et al., 1995)
(2 API 2000 triple quadrupole tandem mass spectrometers – Applied Biosystems)
NBS by ms/ms: 2004 - 2014
2nd tier test
Succinylacetone (Tyr>210 µM, modified from Allard et al., 2004)
Quality Control Programs
CDC (Quality Control and Proficiency)
ERNDIM
NEQAS UK
SIMMESN
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Confirmation of positive cases
•Plasmatic aminoacids analysis (ionic change chromatography)
NBS by ms/ms: 2004 - 2014
•Urinary organic acids (GC-MS)
•Acylcarnitines (dry blood spots, ms/ms)
•Molecular analysis
•Urinary orotic acid (HPLC) 
•Urinary succinylacetone (GC-MS)
Amino acid disorders
*Phenylketonuria (PKU) / HPA  
*Maple syrup urine disease (MSUD)  
Tyrosinemia type I  
Tyrosinemia type II  
Urea cycle disorders
*Citrullinemia type I  
*Argininosuccinate lyase deficiency (ASA)  
Arginase deficiency (ARG 1) 
NBS by ms/ms: 2004 - 2014
Homocystinuria (CBS deficiency)  
MAT I/III deficiency
Organic acid disorders
3-Methylcrotonyl-CoA carboxylase def. (3MCC)
*Isovaleric aciduria (IVA) 
*Propionic aciduria (PA) 
Fatty acid oxidation disorders
SCHAD deficiency
*MCAD deficiency
*LCHAD deficiency
*Methylmalonic aciduria (mut-/0 and Cbl C, D) 
*Glutaric aciduria type I (GA1) 
*3-Hydroxy-3-methylglutaryl CoA lyase def. (3HMG) 
Malonic aciduria
*VLCAD deficiency
MADD deficiency
*CPT I deficiency
*CPT II deficiency
Carnitine transport defect (CUD) 
*Started in 2004
Disorders Positive screening criteria
Phenylketonuria (PKU) / Hyperphenylalaninaemia Phe >150μM and Phe/Try >1,5
Maple syrup urine disease (MSUD) XLeu >342μM and Val >350μM
Tyrosinemia type I Tyr >210μM and succinylacetone (+)
Tyrosinemia type II Tyr >850μM and succinylacetone (-)
Homocystinuria (CBS deficiency) Met >57μM
Methionine adenosyltransferase deficiency (MAT I/III deficiency) Met >57μM
Citrullinemia type I Cit >200μM
NBS by ms/ms: 2004 - 2014
Argininosuccinate lyase deficiency (argininosuccinic aciduria) ASA >1μM
Arginase deficiency Arg >50μM
3-Methyl crotonyl-CoA carboxylase deficiency C5OH >1μM
Isovaleric aciduria C5 >2μM
Propionic aciduria C3 >5,2μM and C3/C2 >0,3
Methylmalonic aciduria (mut -/0) C3 >5,2μM and C3/C2 >0,3
Glutaric acidemia type I C5DC (>0.2μM)
Methylmalonic aciduria (Cbl C, D) C3 >5,2μM, C3/C2 >0,3 and C3/Met >0,4
3-Hydroxy-3-methylglutaryl CoA lyase deficiency C5OH >1μM and C6DC >0,07μM
Malonic aciduria C3DC >0,4μM
Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) C8 >0,3μM and C8/C10 > 2,5
Long-chain 3-OH acyl-CoA dehydrogenase deficiency (LCHAD)
C16OH >0,10μM, C18:1OH >0,07μM,
C18OH >0,06μM and C16OH/C16 >0,04
Multiple acyl-CoA dehydrogenase deficiency (MADD) Multiple elevations from C4 to C18
Carnitine transport defect (CUD) C0 <7μM
Very-long-chain acyl-CoA dehydrogenase deficiency (VLCAD) C14:1 >0,46μM and C14:2 >0,17μM
Carnitine palmitoyl-transferase I deficiency (CPT I) C0/(C16+C18) >30
Carnitine palmitoyl-transferase II deficiency (CPT II) C0/(C16+C18)<3 and (C16+C18:1)/C2>0.5
Short-chain 3-OH acyl-CoA dehydrogenase deficiency (SCHAD) C4OH >1,0μM
NBS by ms/ms – Performance metrics
Number of samples 820.433
Sensitivity 99.42%
Specificity 99.81%
Positive Predictive Value (PPV) 18%
Positive detection rate 1: 2.399
False positive rate 0.19%
•Cut-off adjustments
•New markers (metabolic ratios)
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False negative results
NBS by ms/ms: 2004 - 2014
Methylmalonic aciduria (Cbl D)
C3= 6.1 µM (N<6.2)     Present-day cut-off: C3<5.2 µM
Cut-off adjustment
Argininosuccinic aciduria
Patient 1
CPT II deficiency
C0= 15.1µM (N: 9.1-68)
C2 =  17.2µM (N: 7.0-49)
Met= 15.2 µM (N>6)
C3/met=0.40 (N<0.4)
C3/C2=0.35 (N< 0.3)
Late-onset forms
(p.R250X/ p.R250X)
Cit=23µM (N<50µM)
ASA=0.90µM (N<1.1µM)
Patient 2
Cit= 24 µM (N<50)
ASA= 0.26 µM (N<1.1)
C16=  2.26µM(N: 0.83-7.99)
C18=  1.0µM(N: 0.23-2.28)
C18:1=1.51µM(N: 0.34-3.4)
C18:2= 0.13µM(N: 0-0.8)
C0/(C16 + C18)= 4.6(N: 3-30 )
(C16+C18:1)/C2= 0.22(N <0.5)
(p.S113L/ p.S113L) (p.R12Q/ p.R12Q)
Disorder Positive cases Birth prevalence
Amino acid disorders 127 1: 6 460
Phenylketonuria (PKU) 65 1: 12 622
Hyperphenylalaninaemia 20 1: 41 022
Maple syrup urine disease (MSUD) 4 1: 205 108
Tyrosinemia type I 6 1: 136 739
Tyrosinemia type III 1 1: 820 433
Homocystinuria (CBS deficiency) 2 1: 410 217
Methionine adenosyltransferase deficiency (MAT I/III deficiency) 29 1: 28 291
Urea cycle disorders 16 1: 51 277
Positive cases and birth prevalence: 2004-2014
Citrullinemia type I 9 1: 91 159
Argininosuccinate lyase deficiency 2 1: 410 217
Arginase deficiency 5 1: 164 087
Organic acid disorders 66 1: 12 431
3-Methyl crotonyl-CoA carboxylase deficiency 23 1: 35 671
Isovaleric aciduria 4 1: 205 108
Holocarboxylase synthetase deficiency 2 1: 410 217
Propionic aciduria 3 1: 273 478
Methylmalonic aciduria (mut-/0) 4 1: 205 108
Glutaric aciduria type I 12 1: 68 369
Methylmalonic aciduria (Cbl C/ D) 8+1 1: 91 159
3-Hydroxy-3-methylglutaryl CoA lyase deficiency 8 1: 102 554
Malonic aciduria 1 1: 820 433
Fatty acid oxidation disorders 133 1: 6 169
Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) 98 1: 8 372
Long-chain 3-OH acyl-CoA dehydrogenase deficiency (LCHAD) 7 1: 117 205
Multiple acyl-CoA dehydrogenase deficiency (MADD) 5 1: 164 087
Carnitine transport defect (CUD) 8 1: 102 554
Very-long-chain acyl-CoA dehydrogenase deficiency (VLCAD) 8 1: 102 554
Carnitine palmitoyl-transferase I deficiency (CPT I) 2 1: 410 217
Carnitine palmitoyl-transferase II deficiency (CPT II) 3 1: 273 478
Short-chain 3-OH acyl-CoA dehydrogenase deficiency (SCHAD) 2 1: 410 217
Total (screened newborns: 820 433) 342 1: 2 399
Fatty acid oxidation 
disorders – 39%
Amino acid 
disorders – 37%
NBS by ms/ms: 2004 - 2014
Urea Cycle disorders - 5%
Organic acid
disorders - 19%
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PKU / HPA
MSUD
NBS by ms/ms: 2004 - 2014
Amino acid disorders
Arginase deficiency – 3.5%
Tyrosinemia type I
Tyrosinemia type III
Homocystinuria (CBS 
deficiency)
MAT I/III deficiency
Citrullinemia type I 
PKU / HPA – 59%
(R21X)
Argininosuccinate lyase 
deficiency (ASA)
Arginase deficiency (ARG 1)
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NBS by ms/ms: 2004 - 2014
Fatty acid oxidation disorders 
MCAD deficiency
LCHAD deficiency
MADD
CUD
VLCAD
CPT I
CPT II
SCHAD
MCAD
(A985G)
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3-Methylcrotonyl-CoA 
carboxylase def. (3MCC)
NBS by ms/ms: 2004 - 2014
Organic acid disorders
3HMG – 12%
Isovaleric aciduria (IVA)
Holocarboxylase synthetase 
deficiency
Propionic aciduria (PA)
Methylmalonic aciduria (mut-
/mut0)
Glutaric aciduria type I (GA1)
(E37X)
Methylmalonic aciduria (Cbl 
C/D)
3-Hydroxy-3-methylglutaryl CoA 
lyase def. (3HMG)
Malonic aciduria
Methylmalonic aciduria (Cbl C/D) – 14%
(Cbl C deficiency: c.271dupA)
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